Muhammad Bilal Munir

Muhammad Bilal Munir

Auto-generated profile, based on publicly available information

Muhammad Bilal Munir

Division of Cardiovascular Medicine University of California Davis Sacramento California USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MOMohammed Osman
Mohammed Osman
MSMoinuddin Syed
Moinuddin Syed
BPBrijesh Patel
Brijesh Patel
MMMuhammad Bilal Munir
Muhammad Bilal Munir
BKBabikir Kheiri
Babikir Kheiri
CBChristopher M. Bianco
Christopher M. Bianco
Background: There is increasing utilization of cardiogenic shock treatment algorithms. The cornerstone of these algorithms is the use of invasive hemodynamic monitoring (IHM). We sought to compare the in‐hospital outcomes in patients who received IHM versus no IHM in a real‐world contemporary database. Methods and Results: Patients with cardiogenic shock admitted during October 1, 2015 to December 31, 2018, were identified from the National Inpatient Sample. Among this group, we compared the outcomes among patients who received IHM versus no IHM. The primary end point was in‐hospital mortality. Secondary end points included vascular complications, major bleeding, need for renal replacement therapy, length of stay, cost of hospitalization, and rate of utilization of left ventricular assist devices and heart transplantation. Propensity score matching was used for covariate adjustment. A total of 394 635 (IHM=62 565; no IHM=332 070) patients were included. After propensity score matching, 2 well‐matched groups were compared (IHM=62 220; no IHM=62 220). The IHM group had lower in‐hospital mortality (24.1% versus 30.6%, P <0.01), higher percentages of left ventricular assist devices (4.4% versus 1.3%, P <0.01) and heart transplantation (1.3% versus 0.7%, P <0.01) utilization, longer length of hospitalization and higher costs. There was no difference between the 2 groups in terms of vascular complications, major bleeding, and the need for renal replacement therapy. Conclusions: Among patients with cardiogenic shock, the use of IHM is associated with a reduction in in‐hospital mortality and increased utilization of advanced heart failure therapies. Due to the observational nature of the current study, the results should be considered hypothesis‐generating, and future prospective studies confirming these findings are needed.

22 January 2018 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
SMSayna Matinrazm
Sayna Matinrazm
ALAdetola Ladejobi
Adetola Ladejobi
DPDeepak Kumar Pasupula
Deepak Kumar Pasupula
AJAwais Javed
Awais Javed
ADAsad Durrani
Asad Durrani
SSSamir Saba
Samir Saba

6 October 2013 in EP Europace
Verified
Journal Article
Open access
PDF file
MAMian Bilal Alam
Mian Bilal Alam
MMMuhammad Bilal Munir
Muhammad Bilal Munir
RRRohit Rattan
Rohit Rattan
SFSusan Flanigan
Susan Flanigan
EAEvan Adelstein
Evan Adelstein
SSSamir Saba
Samir Saba
Cardiac resynchronization therapy (CRT) implantable cardioverter defibrillators (ICDs) deliver high burden ventricular pacing to heart failure patients, which has a significant effect on battery longevity. The aim of this study was to investigate whether battery longevity is comparable for CRT-ICDs from different manufacturers in a contemporary cohort of patients. All the CRT-ICDs implanted at our institution from 1 January 2008 to 31 December 2010 were included in this analysis. Baseline demographic and clinical data were collected on all patients using the electronic medical record. Detailed device information was collected on all patients from scanned device printouts obtained during routine follow-up. The primary endpoint was device replacement for battery reaching the elective replacement indicator (ERI). A total of 646 patients (age 69 ± 13 years), implanted with CRT-ICDs (Boston Scientific 173, Medtronic 416, and St Jude Medical 57) were included in this analysis. During 2.7 ± 1.5 years follow-up, 113 (17%) devices had reached ERI (Boston scientific 4%, Medtronic 25%, and St Jude Medical 7%, P < 0.001). The 4-year survival rate of device battery was significantly worse for Medtronic devices compared with devices from other manufacturers (94% for Boston scientific, 67% for Medtronic, and 92% for St Jude Medical, P < 0.001). The difference in battery longevity by manufacturer was independent of pacing burden, lead parameters, and burden of ICD therapy. There are significant discrepancies in CRT-ICD battery longevity by manufacturer. These data have important implications on clinical practice and patient outcomes.

21 June 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
SASiddharth Agarwal
Siddharth Agarwal
CBChristopher W Beard
Christopher W Beard
JKJagjit Khosla
Jagjit Khosla
SCShari Clifton
Shari Clifton
MAMuhammad Faraz Anwaar
Muhammad Faraz Anwaar
ZAZain Ul Abideen Asad
Zain Ul Abideen Asad
Colchicine is an anti-inflammatory drug that may prevent post-operative atrial fibrillation (POAF). The effect of this drug has been inconsistently shown in previous clinical trials. We aimed to compare the efficacy and safety of colchicine vs. placebo to prevent POAF in patients undergoing cardiac surgery. A systematic search of EMBASE, MEDLINE, SCOPUS, ClinicalTrials.gov, and the Cochrane Library for randomized controlled trials (RCTs) was conducted from inception till April 2023. The primary outcome was the incidence of POAF after any cardiac surgery. The secondary outcome was the rate of drug discontinuation due to adverse events and adverse gastrointestinal events. Risk ratios (RR) were reported using the Mantel Haenszel method. A total of eight RCTs comprising 1885 patients were included. There was a statistically significant lower risk of developing POAF with colchicine vs. placebo (RR: 0.70; 95% CI: 0.59–0.82; P < 0.01, I2 = 0%), and this effect persisted across different subgroups. There was a significantly higher risk of adverse gastrointestinal events (RR: 2.20; 95% CI: 1.38–3.51; P < 0.01, I2 = 55%) with no difference in the risk of drug discontinuation in patients receiving colchicine vs. placebo (RR: 1.33; 95% CI: 0.93–1.89; P = 0.11, I2 = 0%). This meta-analysis of eight RCTs shows that colchicine is effective at preventing POAF, with a significantly higher risk of adverse gastrointestinal events but no difference in the rate of drug discontinuation. Future studies are required to define the optimal duration and dose of colchicine for the prevention of POAF.

1 December 2020 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
AAAnas A. Alharbi
Anas A. Alharbi
MKMuhammad Z. Khan
Muhammad Z. Khan
MOMohammed Osman
Mohammed Osman
MKMuhammad U. Khan
Muhammad U. Khan
MMMuhammad B. Munir
Muhammad B. Munir
SBSudarshan Balla
Sudarshan Balla

15 September 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MSMoinuddin Syed
Moinuddin Syed
MKMuhammad Zia Khan
Muhammad Zia Khan
MOMohammed Osman
Mohammed Osman
AAAnas Alharbi
Anas Alharbi
MKMuhammad Usman Khan
Muhammad Usman Khan
SBSudarshan Balla
Sudarshan Balla